An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration

BMC Pharmacology and Toxicology

Volumn 13, Issue , 2012, Pages

  D'Arcy, Deirdre M ^b   Casey, Eoin ^a   Gowing, Caitriona M ^a   Donnelly, Maria B ^a   Corrigan, Owen I ^b  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Amikacin; Haemodiafiltration; Pharmacokinetics

Indexed keywords

AMIKACIN; CREATININE; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTINUOUS HEMODIAFILTRATION; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DIALYSATE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; MALE; OPEN STUDY; PROSPECTIVE STUDY; ULTRAFILTRATION; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; CRITICAL ILLNESS; HEMODIAFILTRATION; METHODOLOGY; MIDDLE AGED;

AGED; AMIKACIN; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; FEMALE; HEMODIAFILTRATION; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROSPECTIVE STUDIES;

EID: 84878078549     PISSN: 20506511     EISSN: None     Source Type: Journal    
DOI: 10.1186/2050-6511-13-14     Document Type: Article

References (26)

1. Leone M, Martin C. Antibiotics in the ICU. 25 years of progress and innovation in intensive care medicine 2007, Berlin: Medizinisch Wissenschaftliche Verlagsgesellschaft, Kuhlen R, Moreno R, Ranierie M, Rhodes A.
2. Kelly CP, LaMont T. Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the basics) http://www.uptodate.com Accessed 20/04/2012.
3. Bristol-Myers Squibb HL. Amikacin Injection 100mg/2ml Summary of Product Characteristics 2012, Dublin: Irish Pharmaceutical Healthcare Association - medicines information online.
4. Winters M. Basic Clinical Pharmacokinetics 2010, New York: Lippincott Williams and Wilkins, 5.
5. Moore R, Smith C, Lietman P. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 1984, 77:657-662. 10.1016/0002-9343(84)90358-9, 6385693.
6. Moore R, Lietman P, Smith C. Clinical Response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987, 155(1):93-99. 10.1093/infdis/155.1.93, 3540140.
7. Roberts J, Kruger P, Paterson D, Lipman J. Antibiotic resistance- What's dosing got to do with it?. Crit Care Med 2008, 36(8):2433-2440. 10.1097/CCM.0b013e318180fe62, 18596628.
8. Barletta J, Johnson S, Nix D, Nix L, Erstad B. Population pharmacokinetics in critically ill trauma patients on once-daily regimens. J Trauma 2000, 49(5):869-872. 10.1097/00005373-200011000-00013, 11086778.
9. Zaske D, Strate R, Kohls P. Amikacin pharmacokinetics: wide interpatient variation in 98 patients. J Clin Pharmacol 1991, 31(2):158-163.
10. Lugo G, Castaneda-Hernandez G. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Crit Care Med 1997, 255:806-811.
11. Udy A, Roberts J, Lipman J. Implications of augmented renal clearance in critically ill patients. Nat Rev Nephrol 2011, 7(9):539-543.
12. Robert R, Rochard E, Malin F, Bouquet S. Amikacin pharmacokinetics during continuous veno-venous hemofiltration. Crit Care Med 1991, 19(4):588-589. 10.1097/00003246-199104000-00029, 2019152.
13. Armendariz E, Chelluri L, Ptachcinski R. Pharmacokinetics of amikacin during continuous venovenous hemofiltration. Crit Care Med 1990, 18(6):675-676. 10.1097/00003246-199006000-00023, 2344762.
14. Akers K, Cota J, Frei C, Chung K, Mende K, Murray C. Once-daily amikacin dosing in burns patients treated with continuous venovenous hemofiltration. Antimicrob Agents Chemother 2011, 55(10):4639-4642. 10.1128/AAC.00374-11, 3186982, 21825289.
15. Pea F, Pierluigi V, Pavan F, Furlanut M. Pharmacokinetic considerations for Antimicrobial Therapy in Patients Receiving Renal Replacement Therapy. Clin Pharmacokinet 2007, 46(12):997-1038. 10.2165/00003088-200746120-00003, 18027987.
16. Moon S-Y, Oh K-H, Oh Y, Curie A, Joo K, Kim Y, Han J, Kim S, Lee J, Kim J-R, et al. Removal of amikacin in patients undergoing continuous veno-venous hemodiafiltration. The Korean J Nephrology 2006, 25(4):595-601.
17. Taccone FS, de Backer D, Laterre P-F, Spapen H, Dugernier T, Delattre I, Wallemacq P, Vincent J-L, Jacobs F. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents 2011, 37(6):531-535. 10.1016/j.ijantimicag.2011.01.026, 21489756.
18. Kinowski J, Coussaye JD, Bressole F, Fabre D, Saissi G, Bouvet O, Galtier M, Eledjam J. Muliple-dose pharmacokinetics of amikacin and ceftaizidime in critically ill patients with septic multiple-organ failure during intermittent haemofiltration. Antimicrob Agents Chemother 1993, 37(3):464-473. 10.1128/AAC.37.3.464, 187694, 8460915.
19. Layeux B, Taccone F, Fagnoul D, Vincent J-L, Jacobs F. Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010, 54:4939-4941. 10.1128/AAC.00441-10, 2976156, 20823287.
20. Jelliffe R, Jelliffe S. A computer program for estimation of creatinine clearance from unstable serum creatinine levels, age, sex and weight. Math Biosci 1972, 14(1-2):17-24.
21. Bressolle F, Gouby A, Martinez J-M, Joubert P, Saissi G, Guillaud R, Goment R. Population pharmacokinetics of amikacin in critically ill patients. Antimicrob Agents Chemother 1996, 40(7):1682-1689. 163395, 8807062.
22. Marik P, Lipman J, Kobilski S, Scribante J. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother 1991, 28:753-764. 10.1093/jac/28.5.753, 1778878.
23. Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis:concepts and applications 2000, Stockholm: Swedish Pharmaceutical Press, 4.
24. Sawchuk R, Zaske D. Pharmacokinetics of dosage regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmackinet Biopharm 1976, 4(2):183-195.
25. Ronchera-Oms C, Tormo C, Ordovas J, Abad J, Jimenez N. Expanded gentamicin volume of distribution in critically ill adult patients receiving total parenteral nutrition. J Clin Pharm Ther 1995, 20(5):253-258. 10.1111/j.1365-2710.1995.tb00659.x, 8576291.
26. Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and reccomendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009, 29(5):662-577.